Multiple Sclerosis (MS) Drugs Market Size to Hit Sales of $31.2 Bn by 2028 | Biogen, Novartis, and Roche Hold Over 55% Share of Multiple Sclerosis Drugs
11 oct. 2022 04h10 HE
|
Vantage Market Research
WASHINGTON, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Global multiple sclerosis drugs market size was $25.1 Billion in 2021 and is estimated to generate revenue of $31.2 Billion by 2028 at a CAGR of 3.7%...
Global Neurological Biomarkers Market is Expected to Reach $18.9 Billion by 2031: Says AMR
27 sept. 2022 12h00 HE
|
Allied Market Research
Portland, OR, Sept. 27, 2022 (GLOBE NEWSWIRE) -- A new business intelligence report released by Allied Market Research, the global Neurological Biomarkers Market size was estimated at $5.4 billion...
U.S. Patent Office Issues Trethera Composition of Matter Patent Covering TRE-515, Extending Market Exclusivity to Late 2041
20 sept. 2022 12h47 HE
|
Trethera Corporation
LOS ANGELES, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Trethera and UCLA Publish Data Demonstrating TRE-515 Ability to Control and Improve Multiple Sclerosis Symptoms in Mouse Models
07 sept. 2022 12h37 HE
|
Trethera Corporation
LOS ANGELES, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 in the Treatment of Acute Disseminated Encephalomyelitis
30 août 2022 10h37 HE
|
Trethera Corporation
LOS ANGELES, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of...
Trethera Receives U.S. Patent Office Notice of Allowance Covering TRE-515 Structural Claims, Extending Protections to Late 2041
17 août 2022 12h38 HE
|
Trethera Corporation
LOS ANGELES, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis
15 août 2022 07h00 HE
|
Clene Inc.
CNM-Au8 met primary and secondary endpoints of Low Contrast Letter Acuity (LCLA) and modified Multiple Sclerosis Functional Composite (mMSFC) compared to placebo over 48 weeks in the mITT...
Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 for the Treatment of Demyelinating Optic Neuritis
09 août 2022 12h47 HE
|
Trethera Corporation
LOS ANGELES, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
NeurologyLive® Announces Giants of Multiple Sclerosis™ Inaugural Class of Inductees
03 juin 2022 09h56 HE
|
NeurologyLive®
CRANBURY, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- NeurologyLive® and the Consortium of Multiple Sclerosis Centers (CMSC) today announced the inaugural class of Giants of Multiple Sclerosis™...
Multiple Sclerosis Drugs Market Size & Trends 2022 - 2028 [CAGR 3.9%] | Industry Share, Growth by Fortune Business Insights
30 mai 2022 04h00 HE
|
Fortune Business Insights
Pune, India, May 30, 2022 (GLOBE NEWSWIRE) -- The global multiple sclerosis drugs market size was worth USD 23.68 billion in 2021. The market valuation is projected to increase from USD 25.43...